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Inhibition of transforming growth factor- restores
endothelial thromboresistance in vein grafts
Navin K. Kapur, MD,a,b Ce Bian, MD,a Edward Lin, MD,a Clayton B. Deming, MS,a
Jason L. Sperry, MD,c Baranda S. Hansen, MS,a Nikolaos Kakouros, MBBS, PhD,a and
Jeffrey J. Rade, MD,a Baltimore, Md; and Boston, Mass
Background: Thrombosis is a major cause of the early failure of vein grafts (VGs) implanted during peripheral and coronary
arterial bypass surgeries. Endothelial expression of thrombomodulin (TM), a key constituent of the protein C anticoagulant
pathway, is markedly suppressed in VGs after implantation and contributes to local thrombus formation. While stretch-
induced paracrine release of transforming growth factor- (TGF-) is known to negatively regulate TM expression in heart
tissue, its role in regulating TM expression in VGs remains unknown.
Methods: Changes in relative mRNA expression of major TGF- isoforms were measured by quantitative polymerase chain
reaction (qPCR) in cultured human saphenous vein smoothmuscle cells (HSVSMCs) subjected to cyclic stretch. To determine
the effects of paracrine release of TGF- on endothelial TM mRNA expression, human saphenous vein endothelial cells
(HSVECs)were co-culturedwith stretchedHSVSMCs in the presence of 1D11, a pan-neutralizingTGF- antibody, or 13C4,
an isotype-control antibody.Groups of rabbits were then administered 1D11 or 13C4 and underwent interpositional grafting
of jugular vein segments into the carotid circulation. The effect of TGF- inhibition on TM gene expression was measured by
qPCR; proteinC activating capacity and local thrombus formationweremeasured by in situ chromogenic substrate assays; and
VG remodeling was assessed by digital morphometry.
Results: Cyclic stretch induced TGF-1 expression in HSVSMCs by 1.9  0.2-fold (P < .001) without significant change in
the expressions of TGF-2 and TGF-3. Paracrine release of TGF-1 by stretched HSVSMCs inhibited TM expression in
stationaryHSVECsplaced in co-culture by 5712% (P .03), an effect thatwas abolished in the presence of 1D11. Similarly,
TGF-1 was the predominant isoform induced in rabbit VGs 7 days after implantation (3.5 0.4-fold induction; P< .001).
TGF-1 protein expression localized predominantly to the developing neointima and coincided with marked suppression of
endothelial TM expression (16%  2% of vein controls; P < .03), a reduction in situ activated protein C (APC)-generating
capacity (53%  9% of vein controls; P  .001) and increased local thrombus formation (3.7  0.8-fold increase over vein
controls; P < .01). External stenting of VGs to limit vessel distension significantly reduced TGF-1 induction and TM
downregulation. Systemic administration of 1D11 also effectively prevented TM downregulation, preserved APC-generating
capacity, and reduced local thrombus in rabbit VGs without observable effect on neointima formation and other morpho-
metric parameters 6 weeks after implantation.
Conclusion:TMdownregulation in VGs ismediated by paracrine release of TGF-1 caused by pressure-induced vessel stretch.
Systemic administration of an anti-TGF- antibody effectively prevented TM downregulation and preserved local thrombo-
resistance without negative effect on VG remodeling. (J Vasc Surg 2011;54:1117-23.)
Clinical Relevance: Vein grafts (VGs) are commonly used conduits for coronary and peripheral arterial bypass surgeries.
Thrombosis is a major cause of early VG failure. Trombomodulin (TM), a key component of the anticoagulant protein C
pathway, is downregulated early after VG implantation and facilitates local thrombus formation. We found that paracrine
release of transforming growth factor-1 (TGF-1), caused by pressure-induced stretch,was a potent negative regulator ofTM
in rabbit VGs. Administration of a neutralizing anti-TGF- antibody effectively prevented TM downregulation and reduced
local thrombus generation without adversely affecting long-term VG remodeling. This may represent a novel strategy to
improve patency in patients undergoing arterial bypass procedures.
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doi:10.1016/j.jvs.2011.04.037Autologous saphenous vein grafts (VGs) remain widely
sed conduits for both peripheral and coronary arterial
ypass graft surgeries. Compared with arterial conduits,
Gs are particularly susceptible to thrombotic occlusion,
hich limits the clinical efficacy of these procedures.1 De-
pite the routine use of antiplatelet agents, occlusion rates
s high as 20% to 30% within the first postoperative year
ontinue to be observed for VGs implanted into both the
eripheral and coronary arterial circulations.2-4
Thrombomodulin (TM) is a transmembrane endothe-
ial cell protein essential to maintaining vascular thrombo-
esistance.5 It binds and alters the active site specificity of
hrombin, preventing both thrombin-mediated cleavage of
brinogen and activation of cellular thrombin receptors
hile enabling thrombin-mediated enzymatic activation of
irculating protein C. Activated protein C (APC) degrades
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October 20111118 Kapur et alfactors Va and VIIIa of the coagulation cascade, thereby
inhibiting further thrombin formation.
We previously found that TM expression was pro-
foundly reduced in rabbit VGs in the weeks following
implantation, resulting in a reduced ability of the graft
endothelium to generate APC that directly resulted in
increased local thrombus formation.6 Subsequent studies
identified pressure-induced stretch as the critical hemody-
namic stimulus negatively regulating TM gene expression
in VGs.7 The ability of stretch to negatively regulate endo-
thelial TM expression and function is not confined only to
VGs but appears to be a more general biological response.
In a rat model of acute heart failure, we similarly found that
TM expression by atrial endocardial endothelial cells was
downregulated by pressure overload-induced stretch.8 In
the heart, stretch-induced paracrine release of transforming
growth factor- (TGF-) by cardiac connective tissue was
identified as the primary mediator of TM gene downregu-
lation and impaired APC generating capacity in the overly-
ing endocardial endothelial cells.
The aim of the present study was to investigate the
relationship between TGF- induction and TM regula-
tion in VGs. We first characterized TGF- isoform in-
duction by vascular stretch in vitro and in vivo. We then
explored the utility of systemic administration of a neu-
tralizing anti-TGF- antibody to restore TM expression
and APC generating capacity and reduce local thrombus
formation. Finally, we investigated the effect of TGF-
inhibition on the development of VG remodeling and
neointimal hyperplasia.
METHODS
Cell culture. Surplus saphenous vein segments were
obtained from patients at the time of cardiac bypass surgery
with approval of the Johns Hopkins School of Medicine
and Tufts Medical Center offices of Human Subjects Re-
search. Human saphenous vein endothelial cells (HSVECs)
were isolated by brushing the luminal surface of divided
vein segments with a sterile cotton swab that was then used
to inoculate tissue culture plates containing EGM-2 culture
medium (Cambrex, Walkersville, Md). Once established in
culture, endothelial cells were subjected to fluorescence
activated cell sorting to 99.9% purity with an anti-CD31
monoclonal antibody (#555445; BD Biosciences, San Di-
ego, Calif) as previously described.8 Human saphenous
vein smooth muscle cells (HSVSMCs) were isolated using
the outgrowth technique,9 cultured in low-glucose Dul-
becco’s modified Eagle’s medium (DMEM; Invitrogen,
Carlsbad, Calif) supplemented with 1% L-glutamine, 10%
bovine growth serum (HyClone, Logan, Utah), and anti-
biotics then characterized by positive staining for smooth
muscle cell actin.
In vitro stretch experiments. Cells were cultured in
their respective media to near-confluence on type-I collagen-
coated 6-well Bioflex plates (Flexcell International, Hills-
borough, NC), then subjected to cyclic stretch at 1 Hz at
37°C under 5% CO for the indicated time with an FX-2
4000T Tension Plus System (Flexcell International). To aetermine the effects of paracrine release of TGF- on
ndothelial TM expression in human vascular endothelial
ells, a previously described coculture system was em-
loyed,8 whereby HSVECs were first cultured on 24-mm
iameter Transwell inserts with a 0.4-m pore size (Corn-
ng, Corning, NY) in endothelial cell growth medium-2
EGM-2) medium. When confluent, the inserts were sus-
ended in the individual wells of Bioflex plates containing
onfluent HSVSMCs in endothelial basal medium (EBM)
edium (Cambrex) containing 0.5 g/mL of either
D11, a TGF- pan-neutralizing antibody, or 13C4, an
sotype control antibody (both generously provided by the
enzyme Corporation, Cambridge, Mass). HSVSMCs
ere then subjected to 10% stretch at 1Hz for 16 hours and
M mRNA expression in stationary HSVEC determined
y quantitative polymerase chain reaction (PCR).
Rabbit vein graft model. All animal procedures were
pproved by the Johns Hopkins University Animal Care
nd Use Committee. Interpositional grafting of jugular
ein segments into the carotid circulation was performed in
ale New Zealand White rabbits (Robinson Services,
lemmons, NC) as previously described.6,7 Immediately
efore surgery, 3 mg/kg gentamicin and 250 mg cephazo-
in were administered intravenously for antibiotic prophy-
axis. In a group of rabbits, the surgical protocol was
odified to prevent pressure-induced vessel distension by
xternally stenting VGs with a nondistensible polyethylene
3-gauge needle cover as previously described.7 Stents had
measured lumenal diameter of 2.0 0.0mm and reduced
essel diameter by over 60% compared with unstented vein
rafts. For experiments to determine the effects of TGF-
eutralization, rabbits were intravenously administered 10
g/kg of either the 1D11 or the 13C4 control antibody in
ormal saline biweekly for the indicated times.
Quantitive PCR. mRNA was extracted from cultured
ells and freshly harvested rabbit VGs using Trizol Reagent
Life Technologies). Aliquots of mRNA were reverse-
ranscribed into cDNA using random hexamer primers (Su-
erscript First-Strand Synthesis System for RT-PCR; Invit-
ogen) and real-time quantitative PCR (RT-PCR) was
erformed in triplicate on a 7900HT Sequence Detector
Applied Biosystems) using TaqMan Universal PCR Mas-
ermix (Applied Biosystems) and primers and labeled
robes to the appropriate target gene (see Supplementary
ethods [online only] for a full list of primer/probe se-
uences).
The mean threshold cycle (CT) values for each sample
ere compared with those of a standard curve derived from
erial dilutions of control jugular vein RNA. Gene expres-
ion for endothelial markers were normalized to 18S rRNA
nd CD31.
Western blot and immunohistochemical analyses.
estern blotting was performed using anti-TM antibodies
#236 and #2380; American Diagnostica), anti-CD31 an-
ibody (M0823; Dako, Carpinteria, Calif), and an anti-
GF-1 antibody (MAB240; R&D Systems, Minneapolis,
inn) as previously described.6 Bands were detected byutoradiography and quantified densitometrically using
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Volume 54, Number 4 Kapur et al 1119UN-SCAN-IT software (Silk Scientific, Orem, Utah). Im-
munohistochemical staining was performed on formalin-
fixed and paraffin-embedded sections of rabbit vein grafts
using an antibodies against human TGF-1 latent associ-
ated peptide (AF-246-NA; R&D Systems), rabbit TM (#
236; American Diagnostica), and human PAI-1 (# 395G;
American Diagnostica) with an appropriate biotinylated
secondary antibody and horseradish peroxidase-labeled
streptavidin (Vector Laboratories; Burlingame, CA). Per-
oxidase activity was revealed by either aminoethylcarbazole
(Dako) or diaminobenzidine (Vector).
In situ protein C and thrombin activity assays.
APC-generating capacity and local thrombin generation
were measured in situ on freshly harvested rabbit vein grafts
7 days after implantation using specific chromogenic sub-
strate assays as previously described.6,8 The rate of substrate
conversion was determined spectrophotometrically using a
Zmax Kinetic Microplate Reader (Molecular Devices,
Sunnyvale, Calif), and the amounts of APC and throm-
bin generated per luminal surface area were calculated by
comparison to human APC (American Diagnostica) and
-human thrombin (Sigma-Aldrich, St. Louis, Mo) stan-
dard curves.
Morphometric analysis. Rabbit vein grafts were har-
vested, formalin perfusion-fixed, and paraffin imbedded 6
weeks after implantation. Three to four Movat-stained
transverse sections per graft were digitally imaged with
distance calibration using a Spot RT digital camera (Diag-
nostic Instruments Inc, Sterling Heights, Mich) mounted
on an Olympus BX60 microscope (Olympus, Optical Co,
Tokyo, Japan). The lumen, neointima, and media areas
were masked and measured using SigmaScan Pro 5.0 soft-
ware (SYSTAT Software, Inc, Richmond, Calif), and aver-
age neointima thickness was calculated as previously de-
scribed.6 Mean values for each graft were determined from
the separate sections and used to calculate group means.
Statistical analysis. All data are presented as mean 
SEM. Comparison between two groups is by two-tailed t
tests and between multiple groups by one-way analysis of
variance (ANOVA). Statistically, relationships not other-
wise indicated are to be assumed nonsignificant (P  .05).
RESULTS
Paracrine effect of stretch-induced release of TGF-ß
on endothelial TM expression. As vein segments are
subjected to pressure-induced stretch when implanted into
the arterial circulation, we first characterized the effects of
direct mechanical stretch on TM expression in endothelial
cells and TGF- isoform expression in vascular smooth
muscle cells in vitro. HSVECs and smooth muscle cells
(HSVSMCs) were cultured on collagen-coated silastic
membranes and subjected to increasing amounts of cyclic
stretch for 16 hours. Direct stretch caused a dose-dependent
induction of TM expression in endothelial cells (Fig 1,
A) as well as of TGF-1 expression in smooth muscle cells
(Fig 1, B). We previously showed that stretch of cardiac
fibroblasts in vitro and of atrial tissue in vivo causes down-
regulation of endocardial TM expression via paracrine re- (ease of TGF-.8 To determine if a similar phenomenon
ight occur in vein grafts, HSVECs were cultured on
tationary filters suspended in the media of wells containing
SVSMCs subjected to 10% cyclic stretch for 16 hours. In
ontrast to the direct effects of stretch, TM mRNA expres-
ion was significantly reduced in stationary cocultured
SVECs while that of the TGF--responsive PAI-1
RNA expression was markedly increased (Fig 1, C). To
onfirm that endothelial TM downregulation was due to
he paracrine effects of TGF- released by the stretched
mooth muscle cells, 1D11, an antibody that neutralizes all
hree TGF- isoforms, was added to the culture medium.
he 1D11 antibody, but not the isotype control 13C4
ntibody that possesses no TGF- inhibitory properties,
ffectively prevented TM downregulation and PAI-1 up-
egulation in the stationary co-cultured endothelial cells
Fig 1, D).
Expression of TGF-ß isoforms in vein grafts.
GF-1 is known to be induced in rabbit VGs within days
f implantation and persist for at least 6 months.10 Because
ittle is known about induction of other TGF- species, the
elative mRNA expression of the three TGF- isoforms was
etermined in rabbit vein grafts 7 days after implantation
nto the arterial circulation, at the time of the known nadir
n TMmRNA expression.7 Similar to that observed in vitro,
GF-1 mRNA expression was increased in rabbit vein
rafts 3.5-fold (P  .001) compared with ungrafted vein
ontrols, while TGF-2 and TGF-3 expression was un-
hanged (Fig 2,A). Immunostaining revealed that TGF-1
nd PAI-1 protein expression colocalized predominantly to
he developing neointima 7 days after implantation and was
ssociated with loss of TM protein expression in the over-
ying endothelial cells (Fig 2, B, second row panels). In
ontrast, TGF-1 and PAI-1 protein expression was mini-
al in the neointima but localized predominantly in the
dventitia 6 weeks after implantation when TM protein
xpression by the luminal endothelium had returned (Fig
, B, third row panels). To differentiate the effects of
ascular stretch from those of pressure on TGF-1 induc-
ion, a group of VGs was externally stented at the time of
mplantation. Compared with unstented grafts, TGF-1
RNA expression was significantly reduced by stenting,
hile TM expression was preserved (Fig 3), indicating that
tretch, and not the direct effects of pressure, is the critical
emodynamic stimulus responsible for TGF-1 upregula-
ion.
Effect of TGF-ß inhibition on TM expression and
ndothelial thromboresistance in vein grafts. To deter-
ine if inhibition of TGF-1 could prevent stretch-induced
ownregulation of TM and improve VG thromboresis-
ance, rabbits were administered 10 mg/kg intravenously
f either the 1D11 or the 13C4 control antibody biweekly
eginning prior to VG implantation and continuing for 7
ays until graft harvest. Treatment with the TGF--
eutralizing 1D11 antibody effectively prevented stretch-
nduced downregulation of TM gene and protein expres-
ion (Fig 4,A and B) and restored APC-generating capacity
Fig 4, C), which suppressed local thrombus formation as
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October 20111120 Kapur et alFig 1. Effects of cyclic stretch on thrombomodulin (TM) and transforming growth factor- (TGF-) isoform
expression. A, Human saphenous endothelial cells (HSVECs) were subjected to cyclic stretch for 16 hours and the
change in TM mRNA expression was determined by quantitative polymerase chain reaction (PCR). Values shown are
the mean  SEM of n  4/group. *P  .01 versus unstretched controls. B, Human saphenous vein smooth muscle
cells (HSVSMCs) were subjected to cyclic stretch for 16 hours and the change in TGF- isoformmRNA expression was
determined by quantitative PCR. Values shown are the mean  SEM of n  8 to 11/group. Panel insert is a Western
blot showing stretch-induced change in TGF-1 protein expression. *P  .001 versus unstretched controls. C,
HSVECs were co-cultured on stationary filters suspended in the media of wells containingHSVSMCs subjected to 10%
cyclic stretch for 16 hours and the changes in TM and PAI-1 mRNA expression were determined by quantitative PCR.
Values shown are the mean SEM of n 3/group.D,HSVECwere co-cultured on stationary filters suspended in the
media of wells containing HSVSMCs subjected to 10% cyclic stretch for 16 hours in the presence of a pan-neutralizing
anti-TGF- antibody (1D11) or nonneutralizing isotype control antibody (13C4). Changes in TM and PAI-1 mRNA
expression were determined by quantitative PCR. Values are the mean SEM of n 3/group. *P .02 versus static
controls.Fig 2. Transforming growth factor- (TGF-) expression in vein grafts. A, Rabbit vein grafts (VGs) were harvested 7
days after implantation, and relative changes in the mRNA expression of the three major TGF- isoforms and PAI-1
were determined by quantitative polymerase chain reaction (PCR). Values are the mean  SEM of n 4 to 6/group.
*P  .001 and #P  .02 versus ungrafted vein controls. B, Immunostaining for TGF-1 (left column, brown color),
PAI-1 (middle column, brown color) and thrombomodulin (TM) (right column, red color) in rabbit VGs harvested 7 days
and 6 weeks after implantation. Staining in a control jugular vein and carotid artery are shown for comparison.
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Volume 54, Number 4 Kapur et al 1121measured by bound thrombin activity on the graft luminal
surface (Fig 4,D). Administration of 1D11 also suppressed
expression of PAI-1 mRNA, which is known to be induced
by TGF-1 (Fig 4, E).
Effect of TGF- inhibition on vein graft neointima
formation. The induction of TGF-1 has been implicated
in the remodeling of VGs as they adapt to the arterial
circulation.10,11 To determine if antibody-mediated TGF-
 inhibition would alter VG remodeling, rabbits were
intravenously administered 10 mg/kg of either the anti-
TGF- 1D11 or the13C4 control antibody biweekly be-
ginning prior to VG implantation and continuing for 6
weeks until graft harvest. Despite having beneficial effects
on endothelial thromboresistance, administration of the
1D11 antibody had no discernable effects on VG remodel-
ing, including neointima formation (Table).
DISCUSSION
The major findings of this study were (1) TGF-1 was
the predominant TGF- isoform induced in vitro by cyclic
stretch of human vascular fibroblasts and by pressure-
induced stretch of rabbit VG in vivo; (2) paracrine release of
TGF-1 was a potent negative regulator of TM expression
and function in rabbit VGs; (3) systemic administration of
a pan-neutralizing anti-TGF- antibody effectively pre-
vented TM downregulation, restored APC-generating ca-
pacity, and reduced local thrombus formation in rabbit
VGs without altering VG remodeling.
Early VG thrombosis is a multifactorial process result-
ing from a complex interplay of systemic factors, such as
inflammation and hypercoagulation, with factors inherent
to the graft, such as impaired blood flow and endothelial
dysfunction or injury.1 Of these factors, endothelial dys-
function caused by exposure of vein segments to arterial
pressure and flow is the least well understood. We have
previously shown that endothelial TMprotein expression in
VGs is reduced by 95% within days of implantation and
remains depressed for many weeks.6 TM is a key compo-
nent of the protein C anticoagulant pathway that is critical
Fig 3. Effect of external stenting on transforming growth fac-
tor-1 (TGF-1) and thrombomodulin (TM) mRNA expression in
vein grafts. TGF-1 and TM mRNA expression was measured in
rabbit vein grafts (VGs) with and without external stents 3 days
after implantation. Values are the mean  SEM of n  3 to
4/group. *P  .001 and #P  .02 versus ungrafted vein controls.to maintaining vascular thromboresistance.5 Acquired loss of TMwith consequent reduced capacity to activate protein
has been observed in a number of thrombotic conditions
uch as transplant rejection, atherosclerosis, and especially
epsis where administration of recombinant APC is now an
pproved therapy.12,13 While diminished nitric oxide gen-
ration and increased tissue factor expression are among
ther recognized hemostatic derangements that impair VG
hromboresistance in the early postoperative period, the
mportance of dysfunction of the TM-protein C pathway is
videnced by the ability of targeted restoration of TM
xpression and APC-generating capacity to reduce local
hrombus formation.6,14,15
Modifications to the standard rabbit VG model to alter
arious hemodynamic parameters performed in our labora-
ory revealed that TM expression was inversely propor-
ional to wall tension caused by pressure-induced disten-
ion of the thin-walled veins.7 Adaption of VGs to the
rterial circulation is characterized by medial hypertrophy
nd neointimal hyperplasia, which increase wall thickness
nd thus reduces wall tension over time. With a decline in
all tension, a concurrent rise in TM expression was ob-
erved, though by 6 weeks, the level of TM expression
emained less than that observed in native arteries.We build
n those findings in the current study by demonstrating
hat pressure-induced stretch induced the expression and
elease of TGF-1, which acts in a paracrine fashion to
uppress endothelial TM expression. This mechanism is
imilar to that observed in a rat model of acute heart failure,
here paracrine release of TGF- inhibited endocardial
M expression in pressure-overloaded left atria.8
The TGF- family encompasses a wide array of pleio-
ropic growth factors intimately involved in inflammation,
ound repair, angiogenesis, and tissue remodeling.16,17
GF-1 mRNA expression is known to be induced in VGs
n the days after implantation in several different animal
odels.18-21 In rabbit VGs, TGF-1 upregulation persists
or at least 6 months and is temporally associated with
yofibroblast recruitment and matrix deposition that oc-
ur during vessel remodeling.10,11,19 Our findings add to
hese data by demonstrating that TGF-1 is the dominant
GF- isoform induced in VGs, that the primary stimulus
or induction is vessel stretch rather than the direct effects
f pressure, and that TGF-1 protein localized to the
eveloping neointima early after implantation, concurrent
ith maximal suppression of endothelial TM expression,
ut predominated in the adventitia at later time points
hen endothelial TM expression returned. Although we
ound that systemic administration of a neutralizing anti-
GF- antibody effectively prevented the downregulation of
M expression in the VG endothelium, we did not observe
ny effects on VG remodeling, especially neointima forma-
ion. This is in contrast to a prior study where adenovirus-
ediated expression of anti-sense RNA directed against
GF-1 had amodest net effect at reducing neointima forma-
ion in a ratVGmodel, although the adenovirus vector itself in
his study appeared to stimulate neointima formation.22
While bothTGF- andTGF- are known to be capable1 2
f downregulating TM expression in endothelial cells, ex-
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October 20111122 Kapur et altremely little is known about the molecular mechanism by
which this occurs.23,24 TGF-1 is initially secreted in an inac-
tive form via association with one of several latency-associated
peptides (LAPs) that anchor it to the extracellular matrix in
the interstitial space.25 Biologically active TGF-1 can be
released from the latent complex through proteolytic cleavage
by matrix metalloproteinases and plasmin or through a con-
formational change mediated by the binding of thrombos-
pondin or v integrins to the LAP complex.
26 Active TGF-1
is able to bind specific serine/threonine kinase type I and type
II receptors causing them to dimerize and phosphorylate a
Fig 4. Effect of transforming growth factor- (TGF-
were administered 10 mg/kg of the anti-TGF- 1D11
implantation with two subsequent doses prior to gr
expression was determined by quantitative polymerase
was determined by densitometric analysis of Western b
C, Activated protein C (APC) generating capacity and
thrombus formation, were measured in situ using ch
mined by quantitative PCR analysis. Values shown a
13C4-treated VGs.
Table. Vein graft morphometry 6 weeks after
implantation
Parameter 1D11 (n  8) 13C4 (n  8)
P
value
Lumen area (mm2) 36.3  11.9 42.8  10.4 .65
Neointima thickness (m) 101.5  9.1 112.5  10.2 .39
Neointima area (mm2) 2.1  0.4 2.5  0.4 .36
Medial thickness (m) 108.4  4.6 114.8  12.4 .62
Medial area (mm2) 2.3  0.3 2.8  0.6 .39
Lumen radius/wall
thickness ratio 15.7  2.3 16.9  2.3 .67
Neointima area/external
elastic lamina area ratio 0.07  0.01 0.07  0.01 .98series of downstream effector proteins known as Smads.While nost Smad proteins positively regulate TGF- signal trans-
uction, Smad6 and Smad7 are known to exert inhibitory
ffects. Only one prior study to date has explored the molec-
lar mechanism by which TGF-modulates endothelial TM
xpression. In a study by Sandusky et al, antisense inhibitionof
mad7 potentiated the downregulation of TM by TGF-1 in
ndothelial cells, while antisense inhibition of a splice variant
f Smad6, known as Smad6s, unexpectedly blunted TM
ownregulation.27 Preliminary data in our laboratory indicate
hatTGF-1-inducedTMdownregulation in endothelial cells
s predominantly mediated by activation of Smad3 and
mad4, with little observed role of canonical Smad6 (data not
hown). It is currently not known what signaling pathways
istal to Smad4 activation regulate TM gene transcription,
lthough this remains an area of active investigation.
In summary, our study demonstrates that TMdownregu-
ation in VGs is mediated by stretch-induced paracrine release
f TGF-1. Systemic administration of a neutralizing anti-
GF- antibody effectively restoredTMexpression andAPC-
enerating capacity,which consequently reduced local throm-
us formation. Our findings may have implications for
reventing VG thrombosis in patients after peripheral and
oronary artery bypass surgeries without subjecting them to
he bleeding risks of systemic anticoagulation.
The authors thank Kushal Sanghvi, MSc, for his tech-
ibition on vein graft (VG) thromboresistance. Rabbits
ody or the isotype control 13C4 antibody before VG
rvest on day 7. A, Thrombomodulin (TM) mRNA
n reaction (PCR) analysis. B, TM protein expression
(a representative Western blot shown in right panel).
ound thrombin activity, an indicator of the degree of
genic assays. E, PAI-1 mRNA expression was deter-
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The sequences of primers/probes used for quantitative PCR included:
1) human TM (GenBank #NM_000361)
Forward: 5=CCCAACACCCAGGC TAGCT 3=
Reverse: 5=CGTCGATGTCCGTGCAGAT 3=
6FAM-labeled probe: 5=TGCCCTGAAGGCTACATCCTGGACG3=)
2) human TGF-1 (GenBank #NM_000660)
Forward: 5=CGAGCCTGAGGCCGACTAC3=
Reverse: 5=TCGGAGCTCTGATGTGTTGAA3=
6FAM-labeled probe: 5=CCAAGGAGGTCACCCGCGTGC 3=
3) human TGF-2 (GenBank #NM_000660)
Forward: 5=TATTGCCCTCCTACAGACTTGAGA3=
Reverse: 5=TGGACGCAGGCAGCAATT 3=
6FAM-labeled probe: 5=CCAACCGGCGGAAGAAGCGTC3=)
4) human TGF-3 (GenBank #NM_000660)
Forward: 5=CCTGAGCCAACGGTGATGA3=
Reverse: 5=TCCCGGGTGCTGTTGTAAAG3=
6FAM-labeled probe: 5=CCACGTCCCCTATCAGGTCCTGGC3=)
5) human PAI-1 (GenBank #NM_000602)
Forward: 5=CGAGCCTGAGGCCGACTAC3=
Reverse: 5=TCGGAGCTCTG ATGTGTTGAA3=
6FAM-labeled probe: 5=CCAAGGAGGTCACCCGCGTGC3=
6) rabbit TM (GenBank #AY138902)
Forward: 5=GATGAATGCGACAACGGCTAT3=
Reverse: 5=CGCA AATGCACT CGTAGCT3=
6FAM-labeled probe 5=CCAGGACGAGTGCCGAAACCTCCT3=
7) rabbit TGF-1 (GenBank #XM_002722312)
Forward: 5=TGCGGCAGCTGTACATTGAC3=
Reverse: 5=CAGGGCCAGGACCTTGCT3=
6FAM-labeled probe: 5=CCCTACATCTGGAGGAGCCTGGACACCC3=
8) rabbit TGF-2{Yoshino, 1995 2032/id}
Forward: 5=GATTTCCATCTACAAGACCACGAGGGACTTGC3=
Reverse: 5=CAGCATCAGTTACAT CGAAGGAGAGCCATTCG3=
6FAM-labeled probe: 5= GCAATGGAGAAGAATGCTTCC3=
9) rabbit TGF-3{Kryger, 2007 2034/id}
Forward: 5=CGGCTCAAGAAGCAGAAGGA3=
Reverse: 5=CGGTGCGGTGGAATCATC3=
6FAM-labeled probe: 5= CACCACAACCCTCACCTCATCCTC3=
10) rabbit PAI-1 (GenBank #XM_002712504)
Forward; 5=CTGCTGGTGAATGCCCTCTACT3=
Reverse: 5=CCGTCCGACTTGTGGAAGA3=
6FAM-labeled probe: 5=TTCTCCAAGTCTGGCACCCACCACCTA3=
11) rabbit CD31{889}
Forward: 5= AACTTCACCATCCAGAAGG 3=
Reverse: 5=CACTGGTATTCCACGTCTT3=
VIC-labeled probe: 5=ACACACGGCTATCTGGACCGCGT3=
